Clinical trial · Observational
A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
A Nationwide, Multi-institutional Retrospective Study of Efficacy and Safety of Eribulin in Korean Breast Cancer Patients
NCT03437083CI-TRIAL-00036742completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective of the study is to observe efficacy in terms of progression-free survival rate at 6 months in eribulin-treated breast cancer participants retrospectively.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced or Metastatic Breast Cancer | Breast Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Eribulin mesylate | Drug | Eribulin | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Eribulin
- description
- Eribulin was administered at a dose of 1.4 milligrams per meters squared (mg/m\^2) (as eribulin 1.23 mg/m\^2) by a 2- to 5-minute intravenous infusion or as a diluted solution on Day 1 and Day 8 every 21 days.
- interventionNames
- Drug: Eribulin mesylate
Primary outcomes (1)
- measure
- Progression-free survival (PFS) rate at 6 months
- timeFrame
- 6 months
- description
- PFS rate at 6 months is estimated based on the tumor response evaluation and is defined as the proportion of participants alive and progression-free at 6 months from the initial treatment of eribulin.
Secondary outcomes (22)
- measure
- Progression-Free Survival (PFS)
- timeFrame
- From the start date of therapy with eribulin to the date of disease progression or death from any cause (1 day to up to approximately 2 years)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Confirmed diagnosis of locally advanced or metastatic breast cancer * Participants who were treated with Eribulin between 01 June, 2014 and 31 December, 2016 Exclusion Criteria: * Not applicable
References
Publications (0)
Data not yet available
No reference posted for this study.